Viral Adapter Molecules for Target-Specific Virotherapy Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viruses like VSV exhibit broad tropism, leading to significant consumption by healthy cells and reduced efficacy in cancer therapy, while viral vectors like LVVs lack target cell specificity for in vivo gene therapy, particularly in lung epithelial cells and T cells, necessitating improved tropism modification.
Innovation Solution
Development of adapter molecules comprising anchoring components derived from LDLR cysteine-rich repeats and targeting components like DARPin or specific ligands to direct VSV and LVV vectors to target cells, enhancing selectivity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If VSV is used for oncolytic virotherapy, then it exhibits broad tropism and can infect many cell types, but most viral particles are consumed by healthy cells and inactivated, reducing effective OV titer and therapeutic efficacy
Solution Approach 1:
The patent uses adapter molecules as intermediaries that consist of an anchoring component (binding to VSV-G) and a targeting component (binding to tumor-specific receptors). These adapters redirect viral particles from healthy cells to tumor cells, resolving the contradiction between broad tropism and therapeutic efficacy by mediating selective delivery to target cells.
2Productivity
If VSV-G pseudotyped vectors are used for gene therapy, then they exhibit high transduction efficiency, but they lack target cell specificity and transduce non-target cells
Solution Approach 1:
The patent applies local quality by modifying the viral vector surface with adapter molecules that have localized targeting functions. The anchoring component maintains high transduction efficiency while the targeting component provides localized specificity to tumor cells, resolving the contradiction between productivity and manufacturing precision.
3Manufacturing precision
If adapter molecules are added to improve target specificity, then off-target effects are reduced, but the system complexity increases
Solution Approach 1:
The patent uses composite adapter molecules that combine anchoring and targeting components into a single functional unit. This composite structure improves target specificity while minimizing system complexity by integrating multiple functions into one molecule rather than requiring separate components.
Data Source
AI summary
The present invention relates to compositions and methods for producing target-specific therapeutic agents with improved properties, useful in oncolytic viro therapy, gene therapy, cell therapy and immunotherapy. Specifically, the invention in embodiments thereof relates to adapter molecules, capable of directing viruses and viral vectors to specific target cells ex vivo and in vivo, to methods for their preparation and use, and to therapeutic compositions comprising them.